Kaufman Rossin Wealth LLC Makes New Investment in BioMarin Pharmaceutical Inc. $BMRN

Kaufman Rossin Wealth LLC purchased a new stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRNFree Report) in the first quarter, HoldingsChannel reports. The firm purchased 6,519 shares of the biotechnology company’s stock, valued at approximately $461,000.

A number of other large investors have also added to or reduced their stakes in BMRN. Nuveen LLC acquired a new position in BioMarin Pharmaceutical in the 1st quarter valued at $184,475,000. Northern Trust Corp increased its position in shares of BioMarin Pharmaceutical by 16.2% in the fourth quarter. Northern Trust Corp now owns 1,725,039 shares of the biotechnology company’s stock worth $113,387,000 after purchasing an additional 240,681 shares during the period. Charles Schwab Investment Management Inc. raised its stake in BioMarin Pharmaceutical by 7.6% in the first quarter. Charles Schwab Investment Management Inc. now owns 1,532,314 shares of the biotechnology company’s stock valued at $108,319,000 after purchasing an additional 108,806 shares in the last quarter. AQR Capital Management LLC lifted its position in BioMarin Pharmaceutical by 114.5% during the fourth quarter. AQR Capital Management LLC now owns 1,283,599 shares of the biotechnology company’s stock worth $84,371,000 after purchasing an additional 685,099 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in BioMarin Pharmaceutical by 19.8% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,055,087 shares of the biotechnology company’s stock worth $69,351,000 after buying an additional 174,634 shares in the last quarter. Institutional investors and hedge funds own 98.71% of the company’s stock.

BioMarin Pharmaceutical Stock Up 1.1%

Shares of NASDAQ BMRN opened at $57.96 on Thursday. The company has a 50 day simple moving average of $57.43 and a 200 day simple moving average of $61.45. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.56 and a quick ratio of 3.60. BioMarin Pharmaceutical Inc. has a 1 year low of $52.93 and a 1 year high of $94.64. The firm has a market cap of $11.13 billion, a PE ratio of 17.20, a price-to-earnings-growth ratio of 0.74 and a beta of 0.18.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on BMRN. Guggenheim boosted their target price on shares of BioMarin Pharmaceutical from $101.00 to $106.00 and gave the company a “buy” rating in a research report on Wednesday, August 6th. Wedbush restated an “outperform” rating and set a $94.00 target price on shares of BioMarin Pharmaceutical in a research note on Tuesday, August 5th. The Goldman Sachs Group decreased their price target on BioMarin Pharmaceutical from $124.00 to $104.00 and set a “buy” rating on the stock in a research note on Monday, May 5th. Morgan Stanley lowered their price target on BioMarin Pharmaceutical from $97.00 to $96.00 and set an “overweight” rating for the company in a report on Tuesday, July 22nd. Finally, Citigroup reduced their price objective on BioMarin Pharmaceutical from $82.00 to $78.00 and set a “neutral” rating on the stock in a research note on Friday, May 2nd. Eighteen investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $93.17.

Get Our Latest Analysis on BioMarin Pharmaceutical

About BioMarin Pharmaceutical

(Free Report)

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

Featured Articles

Want to see what other hedge funds are holding BMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioMarin Pharmaceutical Inc. (NASDAQ:BMRNFree Report).

Institutional Ownership by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.